Shares of Fulcrum Therapeutics (NASDAQ: FULC) , an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial readout. Investors excited about the company's sickle-cell disease candidate pushed the stock 76% higher as of 10:35 a.m. EDT on Monday.
This morning Fulcrum Therapeutics shared data from the company's first clinical trial. The phase 1 study with healthy volunteers showed the company's lead candidate, FTX-6058, was well tolerated and likely to be an effective treatment for people born with sickle cell disease (SCD) and other hemoglobin-related disorders.
Image source: Getty Images.
For further details see:
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today